Overview

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of CTP-499 following single dose administration.
Phase:
Phase 1
Details
Lead Sponsor:
Concert Pharmaceuticals
Treatments:
Pentoxifylline